Bristol-Myers Squibb enters the first week of June in an uncomfortable spot: the stock has shed 6.2% over the past week and 6.5% over the past month, while short sellers have been quietly rebuilding positions at the fastest pace in months.
The most striking development is in the short interest data. Short interest has risen 42% in the last month — climbing from roughly 29.8 million shares in early May to 41.6 million now, equivalent to 2% of free float. That remains a low absolute level, so there is no squeeze dynamic at work. But the pace of accumulation is notable: the build began in earnest after mid-May and accelerated through the final days of the month. Bears are not crowded, but they are growing. Borrow costs are trivial at 0.60% — essentially free to short — and availability in the lending pool is vast, meaning new short positions face no friction whatsoever from the lending market. The setup is one of easy entry for any investor who wants to lean against the stock.
Options positioning has shifted incrementally more defensive. The put/call ratio has moved to 0.93, running about 1.7 standard deviations above its 20-day average of 0.88. That is not an extreme reading — the 52-week high is 1.12 — but the direction of travel aligns with the short interest build: hedging demand has quietly ticked up as the stock has weakened. Combined with a short score of 33.6 that has drifted higher through the past two weeks, the overall picture is one of creeping caution rather than outright bearish conviction.
The Street, broadly, remains constructive on the name. The consensus sits at buy, with six analysts holding positive ratings and a mean price target of $63.08 — roughly 16% above the current $54.46. The most recent move of note came from B of A Securities in early April, trimming its target marginally to $67 while keeping its Buy rating intact. Bulls point to BMY's position in immuno-oncology and a dramatic forward earnings recovery — with 12-month forward EPS growth projected to be among the strongest in recent years. Bears counter with intensifying competition, a heavy US revenue concentration, and potential delays to Phase 3 readouts for Cobenfy. Factor scores reflect that tension: the EV/EBIT percentile rank is strong at 79, the dividend score is at an almost perfect 99, but EPS momentum at 30 and 90 days sits in the mid-40s — not compelling.
The CFO's disposal of roughly $1.85 million in shares on April 1 is worth registering, though the trade carries only low significance scoring and sits within the range of routine executive liquidity. Net insider activity over the 90-day window is a small positive on shares, driven almost entirely by award grants rather than open-market purchases. There is no meaningful insider buying signal here — executives have been taking money off the table as the stock traded in the low $60s, which now looks like wise timing given where the price has landed.
The Q1 print in late April produced a muted immediate response: the stock rose just over 1% on the day but gave it all back within the week, finishing five days later roughly 2.3% lower. The next catalyst is the Q2 report, pencilled in for July 30. Between now and then, the question for traders is whether the ongoing short interest build reflects concern about that print, about pipeline readouts, or simply about the broader pharmaceutical sell-off that has dragged down close peers including GSK (down 5.4% on the week) and AZN (down 5.3%) in similar fashion. The July earnings date is now the clearest near-term marker to watch.
See the live data behind this article on ORTEX.
Open BMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
